Key insights
- BMO Capital reiterated an Outperform rating on Eli Lilly (LLY) with a $1,300 price target, citing positive early Phase 1 data for a new JAK2 inhibitor (AJ1-11095) that shows competitive and durable responses in myelofibrosis patients. This data supports Lilly's business development strategy and positions the drug as potentially best-in-class. Additionally, recent FDA approval for a new dosing regimen of Ebglyss and promising Phase 3 data for the obesity drug Retatrutide further bolster the company's outlook.
Investing.com - BMO Capital reiterated an Outperform rating on Eli Lilly and Company (NYSE:LLY) with a $1,300.00 price target. The pharmaceutical giant, with a market capitalization of $1.01 trillion, has delivered a 39% return over the past year, trading at $1,133.91.
The firm commented on early Phase 1 data for AJ1-11095, a Type 2 JAK2 inhibitor recently acquired by Eli Lilly, presented at the European Hematology Association meeting. The data showed competitive results compared to currently approved treatments.
AJX-101 tested AJ1-11095 in a broad population of myelofibrosis patients who failed Type 1 JAK2 inhibitors. As of the May 28, 2026 data cut, 70% of patients achieved a best SVR35 response at any time.
BMO Capital stated the early responses seen in the abstract release remained durable in the later cut presented at the conference. The firm described the data as highly competitive.
The analyst said the results position AJ1-11095 as a potentially best-in-class JAK2 inhibitor and are supportive of Eli Lilly’s business development strategy. According to InvestingPro analysis, which currently shows the stock as slightly overvalued, Lilly maintains a perfect Piotroski Score of 9. For deeper insights, investors can access the comprehensive Pro Research Report, available for LLY and 1,400+ other US equities.
In other recent news, Eli Lilly and Company received approval from the U.S. Food and Drug Administration for a new dosing regimen of its drug Ebglyss, allowing for an injection every eight weeks for patients with moderate-to-severe atopic dermatitis. This new regimen reduces the frequency of maintenance injections to six per year, down from the previous once-monthly dosing. Additionally, Eli Lilly’s obesity and diabetes drug Retatrutide has garnered attention following the presentation of Phase 3 trial data. The TRIUMPH-1 and TRANSCEND-1 trials showed significant weight loss results, with the 4mg dose achieving 17% weight loss and the 12mg dose resulting in approximately 30% weight loss.
Bernstein SocGen Group reiterated an Outperform rating for Eli Lilly, citing the promising data from these trials. Truist Securities also maintained a Buy rating, highlighting Retatrutide’s substantial efficacy at a low dose and its potential for widespread adoption. The oral GLP-1 therapies for obesity are gaining traction in the U.S. market, although current prescription penetration remains modest. These developments underscore Eli Lilly’s efforts to expand its portfolio in the obesity and diabetes sectors.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
ProPicks AI evaluates LLY alongside thousands of other companies every month using 100+ financial metrics. Using powerful AI to generate exciting stock ideas, it looks beyond popularity to assess fundamentals, momentum, and valuation. The AI has no bias—it simply identifies which stocks offer the best risk-reward based on current data with notable past winners that include Super Micro Computer (+185%) and AppLovin (+157%). Want to know if LLY is currently featured in any ProPicks AI strategies, or if there are better opportunities in the same space?